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A phospholipase D2 inhibitor, 
CAY10594, ameliorates 
acetaminophen-induced acute 
liver injury by regulating the 
phosphorylated-GSK-3β/JNK axis
Sung Kyun Lee1,5, Geon Ho Bae1, Ye Seon Kim1, Hyung Sik Kim1, Mingyu Lee2, 
Jaewang Ghim3, Brian A. Zabel4, Sung Ho Ryu  3 & Yoe-Sik Bae1,2
We examined the role of phospholipase D2 (PLD2) on acetaminophen (APAP)-induced acute liver injury 
using a PLD2 inhibitor (CAY10594). 500 mg/kg of APAP challenge caused acute liver damage. CAY10594 
administration markedly blocked the acute liver injury in a dose-dependent manner, showing almost 
complete inhibition with 8 mg/kg of CAY10594. During the pathological progress of acute liver injury, 
GSH levels are decreased, and this is significantly recovered upon the administration of CAY10594 
at 6 hours post APAP challenge. GSK-3β (Serine 9)/JNK phosphorylation is mainly involved in APAP-
induced liver injury. CAY10594 administration strongly blocked GSK-3β (Serine 9)/JNK phosphorylation 
in the APAP-induced acute liver injury model. Consistently, sustained JNK activation in the cytosol and 
mitochondria from hepatocytes were also decreased in CAY10594-treated mice. Many types of immune 
cells are also implicated in APAP-induced liver injury. However, neutrophil and monocyte populations 
were not different between vehicle- and CAY10594-administered mice which are challenged with APAP. 
Therapeutic administration of CAY10594 also significantly attenuated liver damage caused by the 
APAP challenge, eliciting an enhanced survival rate. Taken together, these results indicate that PLD2 
is involved in the intrinsic response pathway of hepatocytes driving the pathogenesis of APAP-induced 
acute liver injury, and PLD2 may therefore represent an important therapeutic target for patients with 
drug-induced liver injury.
Although acetaminophen (APAP), an over-the counter drug, is widely used as an analgesic and antipyretic, 
overdose may cause serious hepatotoxicity due to hepatocellular necrosis1,2. Drug-induced liver injury (DILI) 
is a major problem caused by APAP overdose, and DILI accounts for more than 50% of acute liver failure in 
the United States1. Accumulation of a reactive metabolite of APAP, N-acetyl-p-benzoquinone-imine (NAPQI), 
in hepatocytes stimulates the generation of intracellular reactive oxygen species and subsequent mitochon-
drial dysfunction and DNA damage3. In overdose conditions, oxidation by cytochrome P450 enzymes becomes 
important in the metabolism of APAP, and excess NAPQI binds to SH- groups in cellular proteins, causing cell 
injury4. During this process, the glutathione (GSH) supply is exhausted5. GSH depletion and covalent binding 
of mitochondrial proteins were traditionally thought to directly lead to mitochondrial dysfunction by triggering 
mitochondrial permeability transition, resulting in hepatocyte death and liver injury. Recent studies suggest that 
GSH depletion and impaired mitochondria function can lead to release of reactive oxygen species that subse-
quently can activate c-Jun N-terminal kinase (JNK), a member of the MAPK family6. Activated JNK translocates 
to the mitochondria, which leads to mitochondrial dysfunction through mitochondrial permeabilization and 
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cytochrome c release7,8. Recent reports have shown that GSK-3β is an important mediator causing APAP-induced 
liver injury9. However, the detailed molecular mechanism involved in APAP-induced DILI remains unclear.
Phospholipase D (PLD) is an important lipid-hydrolyzing enzyme that specifically hydrolyzes phosphatidyl-
choline to phosphatidic acid (PA) and choline10. Two different isoforms of mammalian PLD, PLD1 and PLD2, are 
reported to carry two HKD catalytic motifs, one PX and one PH domain10,11. PLD activity is regulated by several 
molecules including phosphoinositide and protein kinase C10,11. Regarding its physiological role, PLD has been 
reported to regulate many different cellular processes including cell proliferation, apoptosis, cell differentiation, 
vesicle transport, and cell migration12–14. Recent reports demonstrated that PLD2 mediates the hypoxic response 
and pathological angiogenesis15 and septic shock in response to bacterial infection16. Very recently, it has been 
reported that phosphatidic acid (PA), a product of PLD enzymatic activity, is elevated during APAP-induced 
acute liver injury and APAP overdose patients17. However, a functional role for PLD, especially PLD2, in the 
pathogenesis of DILI is yet to be investigated. In this study, we examined the role of PLD2 on DILI and the related 
mechanism of action using a PLD2-selective inhibitor.
Results
CAY10594 administration blocks liver damage of the APAP overdose-induced acute liver injury 
model. At first, we investigated the role of PLD2 on acute liver injury using a CAY10594. Injection of APAP 
(500 mg/kg) caused marked liver injury, which was measured by hematoxylin and eosin staining of the livers 
(Fig. 1A). APAP-induced liver injury was almost completely blocked by the administration of a CAY10594 
in a dose-dependent manner (Fig. 1A). APAP-induced hepatocyte death was measured by the TUNEL assay. 
Figure 1. CAY10594 attenuates APAP overdose-induced acute liver injury. (A–C) Mice were orally challenged 
with APAP (500 mg/kg) alone or with various concentrations of CAY10594 (1 to 8 mg/kg) at 1 h before APAP 
injection and were sacrificed 12 h later. (A) Livers were stained with hematoxylin and eosin (magnification, x200 
or x400). (B) Apoptotic cells were visualized as measured by TUNEL histology apoptotic cells were counted at 
x200 magnification. Scale bar, 100μm (A, B left). (C) AST and ALT levels in sera, which was measured at 12 h 
after APAP treatment. (D) Lethal dose APAP (750 mg/kg)-induced mortality was monitored every 12 h for 72 h. 
Data are expressed as the mean ± SEM (n = 5 for B,C, n = 7 for D). *P < 0.05; by t-test compared with treatment 
of APAP in vehicle control mice (B,C). Survival was analyzed by log-rank test. **P < 0.01 (D).  
Data are representative of two independent experiments.
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Hepatocyte apoptosis was induced by APAP, which was also markedly decreased in CAY10594-administered 
mice compared with vehicle-treated mice (Fig. 1B). The protective effects of the CAY10594 against hepatocyte 
apoptosis were strongly induced at 4 or 8 mg/kg (Fig. 1B).
We then measured aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity in 
serum collected from APAP + vehicle or APAP + CAY10594 administered groups. Injection of APAP caused 
marked increase in both AST and ALT levels in serum, which were significantly decreased by CAY10594 in 
dose-dependent manners (Fig. 1C). Administration of 8 mg/kg CAY10594 almost completely blocked the 
increase of AST and ALT levels in APAP mice serum (Fig. 1C). However, PLD1 inhibitor (VU0155069) injection 
did not block increased AST and ALT levels upon APAP administration (data not shown). A lethal dose of APAP 
(750 mg/kg) elicited severe mice mortality within 72 hours (Fig. 1D). However, administration of CAY10594 
significantly blocked the mortality, showing 100% survival for 72 hours (Fig. 1D). Taken together, these results 
indicate that PLD2 inhibitor, but not PLD1 inhibitor, shows strong protective effects against APAP-induced acute 
liver injury.
CAY10594 treatment causes rapid recovery of APAP-induced decreased GSH levels but 
decreases the sustained activation of JNK in the liver. GSH levels have been previously reported to 
be decreased during acute liver injury18. Administration of an overdose of APAP rapidly depletes GSH from the 
liver of mice18. We also observed that GSH levels were strongly decreased at 3 or 6 hours post APAP challenge 
(Fig. 2A). However, GSH levels were markedly recovered in CAY10594 administered mice at 3 or 6 hours after 
the APAP challenge (Fig. 2A). Presumably, inhibition of PLD2 could repair liver injury or block hepatic cell death 
signaling during APAP consumption in the DILI mouse model.
JNK phosphorylation has been reported to be mainly associated with increased acute liver injury8. In this 
study, we also found that the administration of 500 mg/kg APAP strongly induced JNK phosphorylation in the 
liver of vehicle-injected mice (Fig. 2B). At 2 hours post APAP challenge, JNK phosphorylation was apparent in 
the entire liver tissue, and this was markedly attenuated by CAY10594 treatment (Fig. 2B). In addition to JNK, 
extracellular signal-regulated kinase (ERK) is also known as a key mediator of inflammation and oxidative stress. 
Inhibition of ERK activation can attenuate APAP-induced liver injury19. Therefore, we investigated the role of 
PLD2 on APAP-induced MAPK phosphorylation. APAP treatment promoted the levels of phosphorylated-ERK 
in vehicle-injected mice (Fig. 2B). However, APAP-induced ERK phosphorylation was significantly attenuated by 
CAY10594 treatment (Fig. 2B).
Since phosphoryated GSK-3β mediates the early phase of APAP-induced liver injury, we examined the 
effects of CAY10594 on the phosphorylation of GSK-3β, which triggers mitochondrial dysfunction in the liver. 
Figure 2. Effects of PLD2 inhibition on APAP-induced depletion of GSH levels and JNK activation in the liver. 
(A–C) Vehicle or CAY10594 was administered 1 h before APAP treatment (500 mg/kg). (A) Total GSH from 
liver tissues was determined using a commercial GSH assay kit (Enzo Life Sciences Inc, Farmingdale, NY, USA). 
(B,C) Phosphorylation of JNK, ERK, GSK-3β and total JNK, ERK, GSK-3β from whole liver tissue lysates or (C) 
a mitochondria fraction was determined by Western blot analysis. Data are expressed as the mean ± SEM (n = 5 
for A). ***P < 0.001; by t-test compared with the vehicle treated group with APAP administration (A). Data are 
representative of two independent experiments.
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CAY10594 significantly blocks APAP-induced GSK-3β phosphorylation at 2 hours post APAP administration 
(Fig. 2B).
Sustained activation of JNK in the cytosol can lead to translocation of activated JNK to the mitochondria, 
which is associated with the initiation of mitochondrial dysfunction that can lead to hepatocyte necrosis8,20. As 
expected, inhibition of PLD2 led to blockage of phosphorylated-JNK translocation to the mitochondria (Fig. 2C). 
The results suggest that inhibition of PLD2 could prevent mitochondrial dysfunction by inhibiting JNK translo-
cation. Collectively, inhibition of PLD2 may show protective effects against acute liver injury by attenuating JNK 
phosphorylation in the APAP challenge.
CAY10594 administration regulates cytokine and chemokine production but not immune cell 
recruitment after APAP overdose. Overdose drug-induced liver injury is caused by cytosolic reactive 
oxygen species and intrinsic signaling molecules, GSK-3β, JNK and mitochondrial reactive oxygen species, 
which subsequently induce hepatic cell death9. Extrinsic signaling mediators, pro-inflammatory cytokines, and 
damage-associated molecular patterns, have been also closely associated with APAP-induced liver failure21. In 
this study, we tested the effects of the CAY10594 on the expression levels of inflammatory cytokines and chemok-
ines in APAP-induced acute liver injury. The administration of 500 mg/kg APAP strongly increased the levels 
of TNF-α, IL-6, IL-1β, and CCL2 in the sera from the vehicle administered group. However, the increase of 
pro-inflammatory cytokines and chemokine by APAP were restrained by treatment with CAY10594 (Figs. 3A).
Many types of immune cells are largely involved in hepatic injury through the secretion of pro- or 
anti-inflammatory cytokines such as TNF-α, IL-6, IL-1β and IL-1022. These cytokines serve to promote inflam-
mation during APAP-induced hepatotoxicity22. Here, we investigated the effects of CAY10594 on the composition 
of immune cell population in the liver of APAP-challenged mice. The total number of myeloid cells, including 
neutrophils (CD11bhi Ly6G+), mononuclear cells (CD11bhi Ly6C+), and Kupffer cells (CD11bint F4/80hi) showed 
no significant difference in both vehicle- and CAY10594-treated mice after the APAP challenge (Fig. 3B,C).
CAY10594 shows decreased APAP-induced hepatotoxicity in vitro. Acute liver injury can be 
induced by hepatocyte apoptosis in response to APAP challenge in vitro. In this study, we tested the effects of 
CAY10594 on hepatocyte toxicity in response to APAP in primary hepatocytes. Isolated primary hepatocytes 
were stimulated with 10 mM APAP for several lengths of time. We measured LDH release, which is a biomarker 
for cytotoxicity in damaged cells. Hepatocytes were found to be damaged by APAP after 4 hours, and approx-
imately 40% of the cells were damaged at 16 hours. However, CAY10594 treatment significantly decreased the 
Figure 3. Effects of CAY10594 on cytokine production and distribution of immune cells in liver after APAP 
overdose. (A–C) Vehicle or CAY10594 was administered by intraperitoneal injection 1 h before APAP treatment 
(500 mg/kg). (A) Peripheral blood was collected at 12 h after the APAP challenge. The amounts of cytokine 
in the serum were determined by ELISA analysis. (B,C) Primary cells from liver tissue were isolated using 
perfusion with collagenase. These cells were stained against CD11b-PerCP/cy5.5, Ly6G-FITC, Ly6C-PE/
cy7, F4/80-APC and analyzed by flow cytometry. Data are expressed as the mean ± SEM (n = 5–6 for A,C). 
(A) ND = Not detected, (A,C) *P < 0.05; by t-test compared with the vehicle treated group with APAP 
administration (A). Data are representative of two independent experiments.
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APAP-induced hepatocyte damage (Fig. 4A). The addition of APAP into hepatocytes markedly increased the 
death of hepatocytes showing PI+ cells, which were decreased by CAY10594 treatment (Fig. 4B). In vitro stim-
ulation of primary hepatocytes with APAP (10 mM) also induced GSK-3β phosphorylation (Fig. 4C). Addition 
of CAY10594 markedly blocked APAP-induced GSK-3β phosphorylation in primary hepatocytes (Fig. 4C). 
Taken together, the results suggest that PLD2 plays a key role in the intrinsic response pathway of hepatocytes to 
APAP-induced hepatotoxicity.
CAY10594 shows therapeutic effects against APAP overdose-induced acute liver injury. Clinically, 
it is important to develop therapeutic agents against liver damage due to drug overdose. Therefore, we investi-
gated whether CAY10594 shows therapeutic effects against APAP-induced acute liver injury by administering 
CAY10594 after the APAP challenge. Administration of CAY10594 (8 mg/kg) 3 h post APAP challenge markedly 
blocked APAP-induced liver damage, which was measured by histological analysis after hematoxylin and eosin 
staining (Fig. 5A). Mouse survival rate was also highly increased upon 8 mg/kg of CAY10594 administration at 
3 h after APAP challenge, showing an 50% survival rate, respectively (Fig. 5B). Under the same experimental 
conditions, the vehicle administered group after APAP challenge showed a 12.5% survival rate at 72 h (Fig. 5B). 
These results strongly indicate that CAY10594 has therapeutic effects against APAP-induced acute liver injury.
Discussion
PLD regulates lipid metabolism by hydrolyzing phosphatidylcholine to PA and choline23. PLD2 has been 
known to have a far higher basal activity than PLD1, and PLD2 mediates various unique protein interac-
tions24. Moreover, PLD2 has different metabolic properties from PLD1, and most production of cyclic PA is 
Figure 4. CAY10594 blocks APAP-induced primary hepatocyte death. (A–C) Primary hepatocytes were 
isolated from mice liver using collagenase. Cells were preincubated with CAY10594 (10 μM) or not in the 
absence or presence of 10 mM APAP in a time-dependent manner. (A) LDH activity in the supernatant 
was assessed by the LDH cytotoxicity assay kit, and OD values at 490 nm are presented as a line graph. (B) 
To determine hepatocyte death, hepatocytes were stained against propidium iodide (PI) and the number 
of PI positive cells were counted at x200 magnification by fluorescence microscopy. Scale bar, 100μm (B). 
(C) Phosphorylation of GSK-3β and total GSK-3β from primary hepatocytes was determined by Western 
blot analysis. All data are represented as the mean ± SEM. The data are representative of two independent 
experiments. **P < 0.01; by t-test compared with APAP-treated cells given the vehicle (A).
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dependent on PLD2 rather than PLD125. Previously, it was reported that accumulation of PA can enhance 
the regeneration of liver after APAP-induced liver injury17. A separate report demonstrated that inhibi-
tion of PA production with FSG67, an inhibitor of glycerol 3-phosphate acyltransferase, did not affect the 
severity of APAP-induced acute liver injury at the injury phase17. However, in this study, we have observed 
preventive effects of CAY10594, showing 100% survival against the APAP-induced acute liver injury mice 
model (Fig. 1D). CAY10594 also induced strong therapeutic effects in APAP-challenged mice (Fig. 5). The 
results suggest an important role for PLD2, which crucially mediates APAP-induced liver injury. Because 
PLD2 has basal activity, administration of CAY10594 would block the generation of PA, the product of 
PLD2 enzymatic activity, in an experimental acute liver injury model. Therefore, it might reasonable to 
assume that the protective and therapeutic effects of CAY10594 in an acute liver injury model would be 
mediated by blocking the generation of PA. Based on our findings, we suggest that PA may have a patholog-
ical role in the disease progress of acute liver injury.
In APAP-induced acute liver injury, phosphorylation of JNK is a central player in inducing hepatic damage26. 
Sustained phosphorylation of JNK and translocation of JNK to the mitochondria exacerbates mitochondrial 
dysfunction, and causes hepatic necrosis. Moreover, previous reports already demonstrated that JNK inhibi-
tors such as leflunomide, SP600125 or D-JNKI1 inhibited APAP-induced liver injury27,28. JNK phosphorylation 
can be differentially controlled in two different phases, the early and late phase. Phosphorylated-GSK-3β/JNK 
axis is a major source of APAP-induced liver injury at the very early phase. The early phase of JNK activation is 
regulated by GSK-3β, which can activate JNK through MEKK-1 or mixed lineage kinase-dependent pathways. 
On the other hand, the late phase of JNK activation is believed to mediate apoptosis signal-regulating kinase 1. 
Recently, p53 up-regulated modulator of apoptosis has been reported to be induced downstream of JNK and 
mediate APAP-induced necrosis and liver injury29. GSK-3β silencing has been reported to have beneficial effects 
against APAP-induced liver injury. Therefore, we tested whether PLD2 modulates phosphorylated-GSK-3β in the 
early phase following the APAP challenge. CAY10594 almost completely blocked GSK-3β phosphorylation when 
compared with vehicle administered mice (Fig. 2B). Our results suggest that CAY10594 may block JNK phospho-
rylation at the early phase by inhibiting GSK-3β phosphorylation (Fig. 6). At about 30 min to 6 h after the APAP 
challenge, NAPQI, the metabolite of APAP, induces the dysfunction of mitochondria and production of reactive 
oxygen species that initiate liver injury through JNK phosphorylation. Therefore, the regulation of reactive oxy-
gen species is important in APAP-induced liver injury. These reactive oxygen species can be removed by GSH, 
but APAP overdose induces GSH depletion in an hour30. We found that CAY10594 prevents phosphorylation of 
JNK (Fig. 2B) and the regulation of GSK-3β phosphorylation, that might contribute to this mechanism (Fig. 2B). 
APAP challenge-induced GSH depletion was rapidly recovered upon CAY10594 administration (Fig. 2A). Since 
acute liver injury induced by APAP overdose has been reported to be mediated by the generation of excess oxi-
dative stress31, it is important to regulate the expression of anti-oxidant genes in the liver to endure oxidative 
stress32. We also tested for a possible effect of CAY10594 on the regulation of anti-oxidant genes. The expression 
of several anti-oxidant genes, including FGF21, Nrf2, HO-1 and NQO1, were highly expressed upon APAP over-
dose. However, anti-oxidant gene expression was not increased by CAY10594, with the expression levels remain-
ing low compared to vehicle mice at 6 hours post APAP challenge (data not shown). Consequently, it appears 
that CAY10594-induced protective effects against APAP-induced liver injury is not mediated by upregulation of 
Figure 5. CAY10594 elicits therapeutic effects on APAP-induced acute liver injury. (A) After fasting for 16 h, 
APAP (500 mg/kg) was administered to mice. Either the vehicle (PBS containing 1% DMSO) or CAY10594 
(8 mg/kg) was administered to the APAP-challenged mice at 3 h post APAP. The livers were isolated from 
the APAP-challenged mice at 12 h, and stained with hematoxylin and eosin (magnification, x100, x200) (A). 
The data are representative of two independent experiments with individual samples. Each experiment was 
performed in quintuplicates. Scale bar: 200 μm (A). (B) Survival rate was monitored from mice which were 
intraperitoneally injected with either the vehicle (PBS containing 1% DMSO) or CAY10594 (8 mg/kg) at 3 h 
after the APAP challenge (750 mg/kg). The survival rate was monitored every 6 h for 72 h. *P < 0.05 by log-rank 
test. Sample size: n = 8 (B).
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anti-oxidant genes. Collectively, our results suggest that CAY10594 may modulate early hepatopathology to pre-
vent APAP-induced liver injury by rapid recovery of GSH levels without affecting anti-oxidant gene expression.
The pathological progress of acute liver injury caused by APAP administration can be mediated by early 
recruitment and activation of several immune cell types. This immune cell infiltration to the liver in a short 
period of time is regulated by several damaged-associated molecular patterns such as the S-100A families and 
HMGB-1 from hepatocytes21. Immune cells infiltrated into the liver can induce the secretion of inflammatory 
cytokines and chemokines, which contributes greatly to liver damage. In our study, we found that administra-
tion of CAY10594 did not affect the number of CD11bhiLy6C+, CD11bhiLy6G+, and CD11bintF4/80+ cells in 
APAP-challenged mice (Fig. 3C). These results suggest that PLD2 is not involved in immune cell population 
changes during APAP-induced liver damage.
If liver damage is suppressed at early time phases, inflammatory stimuli would not be secreted. TNF-α and 
IL-1β are known as major pro-inflammatory cytokines which play roles in DILI. TNF-α induces mitochon-
drial dysfunction via the TNF-receptor and induces hepatocyte death through caspase activation33. IL-1β is 
also an inflammatory cytokine that induces liver damage and is produced by activation of the inflammasome34. 
CAY10594 efficiently reduced secretion of pro-inflammatory cytokines and the CCL2 chemokine (Fig. 3A). 
Since we also observed that CAY10594 administration suppresses liver damage at the early phase, our results 
suggest that the protective effects of CAY10594 against acute liver injury would be directly mediated by regu-
lation of hepatocytes but not by regulation of immune cell activity. Our findings of the direct inhibitory effects 
of CAY10594 on the hepatotoxicity and GSK-3β phosphorylation caused by APAP treatment (Fig. 4) further 
support our idea that CAY10594 may show protective effects against acute liver injury by modulating hepatocyte 
activity (Fig. 6). On the action mode of CAY10594, the inhibitor can inhibit GSK-3β/JNK axis to regulate ROS 
generation in mitochondria of hepatocytes (Fig. 6).
In APAP-induced liver injury, pharmacological treatment options are highly limited. For APAP overdose 
patients, a prescription of N-acetylcysteine is the only treatment since the 1970’s35. Metformin has also been 
revealed as a therapeutic candidate for APAP-induced liver injury, however, it must be administered at a con-
centration higher than 300 mg/kg like N-acetylcysteine. However, in our study, we demonstrate that CAY10594, 
which has been highlighted as being therapeutic without unacceptable clinical side effects14, has great therapeutic 
Figure 6. Working model of the therapeutic effects of CAY10594 against APAP-induced acute liver injury. 
CAY10594 blocks GSK-3β (Serine 9)/JNK phosphorylation in hepatocytes, eliciting therapeutic effects against 
APAP-induced acute liver injury model.
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effects at a low dosage (8 mg/kg). Based on our current findings, we suggest that CAY10594 can be regarded as an 
important material for the development of therapeutic agents against APAP overdose-induced acute liver injury.
Materials and Methods
Animal study. C57BL/6 mice were purchased from DBL (Eumsung, Korea). All animal experiments were 
performed in accordance with the Korea Food and Drug Administration guidelines. Protocols were approved by 
the Animal Care and Use Committee, Sungkyunkwan University (Suwon, Korea). Mice were fasted for 16 hours 
before APAP injection. APAP (500 mg/kg) was administered with oral gavage in mice. CAY10594 (N-[2-(4-oxo-
1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalene carboxamide)23 was dissolved in 1% DMSO and 
intraperitoneally administered to mice 30 minutes prior to APAP injection for examining protective effects or 
after 3 hours from APAP challenge for investigating therapeutic effects of CAY10594.
Histopathology and immunohistochemistry. Twelve hours after APAP (500 mg/kg) was administered 
with oral gavage in mice, the mice were euthanized, and their livers were isolated and fixed with 10% neutral buff-
ered formalin. Liver tissues were embedded in paraffin and stained with hematoxylin and eosin for morphological 
analysis. The TUNEL assay was performed on paraffin-embedded tissue sections using a standard histological 
protocol. In brief, section slides were incubated using terminal deoxynucleotidyl transferase dUTP nick end 
labeling fluorescein for 1 hour at 37 °C in dark. The samples were washed 3 times in PBS for 3 minutes each and 
incubated with peroxidase conjugated anti-fluorescein antibody for 30 min at 37 °C in the dark. TUNEL positive 
cells were detected by diaminobenzidine solution. Liver histology and apoptotic cells were observed under a Leica 
ICC50 HD microscope.
Measurement of serum AST and ALT. ALT and AST levels were measured using an ALT activity kit and 
AST activity assay kit (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions.
GSH measurements. Liver tissue (33 mg) was homogenized with 5% metaphosphoric acid (500 μl) and cen-
trifuged at 12,000 rpm for 10 minutes at 4 °C. GSH levels were measured from the supernatants using a glutathione 
(GSSG/GSH) detection kit according to the manufacturer’s instructions (Enzo Life Sciences Inc, Farmingdale, 
NY, USA). Total GSH levels were measured according to the net slope of the standard curve.
Mitochondria isolation. Liver tissue (35 mg) was homogenized and used for the fractionation of mito-
chondria using a mitochondria isolation kit (Thermo Fisher ScientificTM, Waltham, MA USA) according to the 
manufacturer’s instructions.
Western blot analysis. Homogenized liver samples or primary hepatocytes were lysed with RIPA buffer 
(150 mM NaCl, Tris-HCl pH 7.5, SDS 0.1%, Triton X-100 1%, EDTA 2 mM, 0.5% Na-deoxycholate) with pro-
teinase inhibitor. Proteins were resolved by SDS-PAGE and transferred to a PVDF membrane, which was probed 
with primary antibodies against phospho-ERK, JNK, GSK-3β (Serine 9) and ERK, JNK, GSK-3β, COX IV (Cell 
Signaling Technology, Danvers, MA, USA) followed by incubation with secondary antibodies conjugated with 
horseradish peroxidase.
Cytokine measurement. Blood samples were collected from acute liver injury mice 12 hours post-APAP 
treatment. Cells were removed from the harvested biofluids by centrifugation (12,000 rpm for 1 minute), and the 
levels of cytokines were measured by ELISA (eBioscience Inc., San Diego, CA, USA).
Flow cytometry. Single cell suspensions of cells from collagenase treated liver samples were generated and 
blocked with FcγIII antibody and stained for CD11b (M1/70), Ly6G (1A8), Ly6C (HK1.4), F4/80 (BM8) on the 
cell surface. All those primary antibodies were purchased from eBioscience (San Diego, CA, USA). Cells were 
analyzed by flow cytometry and data were analyzed by FlowJo_V10.
Isolation of primary hepatocytes and in vitro experiments with APAP treatment. Primary 
hepatocytes were isolated from wild-type mice following liver-specific perfusion with 50 ml of a buffer containing 
66.7 mM NaCl, 6.7 mM KCl, 50 mM HEPES, 4.8 mM CaCl2 2H2O, collagenase type IV. Cells were centrifuged at 
500 rpm for 4 minutes. Primary hepatocytes were separated from dead cells and other cell types by Percoll gradi-
ent centrifugation (1,250 rpm for 5 minutes) and seeded into 6-well culture dishes (Thermo Fisher Scientific), and 
then cells were stimulated with 5~20 mM APAP with time dependency. Stimulated cells were fixed with 4% for-
maldehyde at room temperature for 10 minutes. Next, the cells were washed twice with 1 × PBS and stained with 
PI in 1 × PBS at room temperature for 10 minutes. PI positive cells were visualized with a fluorescence microscope 
(KI-2000F, Korea Lab Tech, Seongnam, Korea) and images were analyzed with OptiView 3.7.
Cytotoxicity assay. Cytotoxicity was assessed by detection of the enzyme lactate dehydrogenase (LDH) 
in the supernatant of the cell culture. The assay was performed using the Cytotoxicity Detection Kit (Promega, 
Madison, WI, USA) according to the manufacturer’s protocol. The LDH concentration in 50 µl of the cell culture 
supernatant was determined at a wavelength of 490 nm. Cells treated with lysis solution served as a reference 
for the maximum possible LDH release (100%, high control). The relative LDH release of a given sample is then 
defined as the ratio of LDH measured in the supernatant of the sample and the high control value with LDH val-
ues under 10% regarded as a nontoxic effect level.
9Scientific RepoRts |          (2019) 9:7242  | https://doi.org/10.1038/s41598-019-43673-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Statistical analysis. Results were evaluated using GraphPad prism software. Statistical analysis was per-
formed by Student’s t-test. All results are expressed as the mean ± SEM. Survival data were analyzed using the 
log-rank test. A P value ≤ 0.05 was considered statistically significant.
References
 1. Larson, A. M. et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 
42, 1364–72 (2005).
 2. Wilcox, C. M., Cryer, B. & Triadafilopoulos, G. Patterns of use and public perception of over-the-counter pain relievers: focus on 
nonsteroidal antiinflammatory drugs. J. Rheumatol. 32, 2218–24 (2005).
 3. Placke, M. E., Ginsberg, G. L., Wyand, D. S. & Cohen, S. D. Ultrastructural changes during acute acetaminophen-induced 
hepatotoxicity in the mouse: a time and dose study. Toxicol. Pathol. 15, 431–8 (1987).
 4. Kon, K., Kim, J.-S., Jaeschke, H. & Lemasters, J. J. Mitochondrial permeability transition in acetaminophen-induced necrosis and 
apoptosis of cultured mouse hepatocytes. Hepatology 40, 1170–9 (2004).
 5. Mitchell, J. R. et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185–94 (1973).
 6. Xu, J. J., Hendriks, B. S., Zhao, J. & de Graaf, D. Multiple effects of acetaminophen and p38 inhibitors: towards pathway toxicology. 
FEBS Lett. 582, 1276–82 (2008).
 7. Han, D., Shinohara, M., Ybanez, M. D., Saberi, B. & Kaplowitz, N. Signal transduction pathways involved in drug-induced liver 
injury. Handb. Exp. Pharmacol. 267–310, https://doi.org/10.1007/978-3-642-00663-0_10 (2010).
 8. Hanawa, N. et al. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-
induced liver injury. J. Biol. Chem. 283, 13565–77 (2008).
 9. Shinohara, M. et al. Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation 
and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J. Biol. Chem. 285, 8244–55 (2010).
 10. Oude Weernink, P. A., López de Jesús, M. & Schmidt, M. Phospholipase D signaling: orchestration by PIP2 and small GTPases. 
Naunyn. Schmiedebergs. Arch. Pharmacol. 374, 399–411 (2007).
 11. Jenkins, G. M. & Frohman, M. A. Phospholipase D: a lipid centric review. Cell. Mol. Life Sci. 62, 2305–16 (2005).
 12. Peng, X. & Frohman, M. A. Mammalian phospholipase D physiological and pathological roles. Acta Physiol. (Oxf). 204, 219–26 (2012).
 13. Park, J. B. et al. Phospholipase signalling networks in cancer. Nat. Rev. Cancer 12, 782–92 (2012).
 14. Frohman, M. A. The phospholipase D superfamily as therapeutic targets. Trends Pharmacol. Sci. 36, 137–144 (2015).
 15. Ghim, J. et al. Endothelial deletion of phospholipase D2 reduces hypoxic response and pathological angiogenesis. Arterioscler. 
Thromb. Vasc. Biol. 34, 1697–703 (2014).
 16. Lee, S. K. et al. Phospholipase D2 drives mortality in sepsis by inhibiting neutrophil extracellular trap formation and down-
regulating CXCR2. J. Exp. Med. 212, 1381–90 (2015).
 17. Lutkewitte, A. J. et al. Lipin deactivation after acetaminophen overdose causes phosphatidic acid accumulation in liver and plasma 
in mice and humans and enhances liver regeneration. Food Chem. Toxicol. 115, 273–283 (2018).
 18. Jaeschke, H., McGill, M. R., Williams, C. D. & Ramachandran, A. Current issues with acetaminophen hepatotoxicity–a clinically 
relevant model to test the efficacy of natural products. Life Sci. 88, 737–45 (2011).
 19. Liu, F.-C., Lee, H.-C., Liao, C.-C., Li, A. H. & Yu, H.-P. Tropisetron Protects Against Acetaminophen-Induced Liver Injury via Suppressing 
Hepatic Oxidative Stress and Modulating the Activation of JNK/ERK MAPK. Pathways. Biomed Res. Int. 2016, 1952947 (2016).
 20. Ong, M. M. K., Latchoumycandane, C. & Boelsterli, U. A. Troglitazone-induced hepatic necrosis in an animal model of silent genetic 
mitochondrial abnormalities. Toxicol. Sci. 97, 205–13 (2007).
 21. Martin-Murphy, B. V., Holt, M. P. & Ju, C. The role of damage associated molecular pattern molecules in acetaminophen-induced 
liver injury in mice. Toxicol. Lett. 192, 387–94 (2010).
 22. Blazka, M. E., Wilmer, J. L., Holladay, S. D., Wilson, R. E. & Luster, M. I. Role of proinflammatory cytokines in acetaminophen 
hepatotoxicity. Toxicol. Appl. Pharmacol. 133, 43–52 (1995).
 23. Scott, S. A. et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat. Chem. Biol. 5, 
108–17 (2009).
 24. Hancock, J. F. NEWS and VIEWS PA promoted to manager. 9, 615–617 (2007).
 25. Tsukahara, T. et al. Article Phospholipase D2-Dependent Inhibition of the Nuclear Hormone Receptor PPAR g by Cyclic 
Phosphatidic Acid. Mol. Cell 39, 421–432 (2010).
 26. Jaeschke, H. Mechanisms of Acetaminophen Hepatotoxicity: Do We Need JNK for Cell Death? Gastroenterology 151, 371–2 (2016).
 27. Latchoumycandane, C., Goh, C. W., Ong, M. M. & Boelsterli, U. A. Mitochondrial protection by the JNK inhibitor leflunomide 
rescues mice from acetaminophen-induced liver injury. Hepatology 45, 412–21 (2007).
 28. Henderson, N. C. et al. Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Gut. 56, 982–90 
(2007).
 29. Chen, D. et al. PUMA induction mediates acetaminophen-induced necrosis and liver injury. Hepatology, https://doi.org/10.1002/
hep.30422 (2018).
 30. Woolbright, B. L. & Jaeschke, H. Role of the Inflammasome in Acetaminophen-induced Liver Injury and Acute Liver Failure. J. 
Hepatol. 66, 836–48 (2017).
 31. Jaeschke, H. Glutathione disulfide formation and oxidant stress during acetaminophen-induced hepatotoxicity in mice in vivo: the 
protective effect of allopurinol. J. Pharmacol. Exp. Ther. 255, 935–41 (1990).
 32. Ye, D. et al. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome 
proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice. Hepatology 60, 977–89 (2014).
 33. Han, D. et al. Regulation of drug-induced liver injury by signal transduction pathways: Critical role of mitochondria. Trends 
Pharmacol. Sci. 34, 243–253 (2013).
 34. Williams, C. D. et al. Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. Toxicol. 
Appl. Pharmacol. 252, 289–97 (2011).
 35. Du, K., Ramachandran, A. & Jaeschke, H. Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role 
and therapeutic potential. Redox Biol. 10, 148–156 (2016).
Acknowledgements
This work was supported by Basic Science Research Program through the National Research Foundation of 
Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2017R1A5A1014560, NRF-
2018R1A2B3003868).
Author Contributions
S.L., G.B., Y.K. and H.K. conducted the experiments of Figures. J.G. and S.R. supplied materials and analyzed 
data. B.A.Z. wrote the manuscript. S.L., G.B., M.L. and Y.B. planned the experiments, analyzed data and wrote 
the manuscript.
1 0Scientific RepoRts |          (2019) 9:7242  | https://doi.org/10.1038/s41598-019-43673-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
